Prelude Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Prelude Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.1K	Sell	13,843 -6,557	-32%	-$26.2K	﹤0.01%	1153
2026 Q1	$47.7K	Buy	+20,400	New	+$52.7K	﹤0.01%	1128
2025 Q2	–	Sell	-18,710	Closed	-$29.7K	–	1437
2025 Q1	$29.7K	Sell	18,710 -800	-4%	-$1.73K	﹤0.01%	1118
2024 Q4	$59.1K	Buy	19,510 +4,300	+28%	+$14.1K	﹤0.01%	1139
2024 Q3	$56K	Buy	+15,210	New	+$55.3K	﹤0.01%	1207
2023 Q4	–	Sell	-10,190	Closed	-$204K	–	1398
2023 Q3	$204K	Buy	10,190 +173	+2%	+$4.39K	0.01%	891
2023 Q2	$283K	Buy	+10,017	New	+$240K	0.02%	677

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Prelude Capital Management's ZNTL Position: Q2 2026 in Review

Prelude Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 32% in Q2 2026, selling an estimated $26.2K and leaving 13,843 shares worth $67.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.

Prelude Capital Management first reported a position in ZNTL in Q2 2023 and has held it in 7 quarters since. The position peaked at $283K in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Prelude Capital Management held 13,843 shares of Zentalis Pharmaceuticals worth $67.1K as of Q2 2026.
Prelude Capital Management sold 6,557 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $26.2K.
Zentalis Pharmaceuticals made up ﹤0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1153 holding.
Prelude Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Prelude Capital Management's Zentalis Pharmaceuticals position peaked at $283K in Q2 2023.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.